Details for Patent: 8,161,968

Which drugs does patent 8,161,968 protect, and when does it expire?

Patent 8,161,968 protects ANORO ELLIPTA, ARNUITY ELLIPTA, BREO ELLIPTA, and TRELEGY ELLIPTA, and is included in four NDAs.

Protection for ANORO ELLIPTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighteen patent family members in seventeen countries.

Summary for Patent: 8,161,968

Title:	Medicament dispenser
Abstract:	There is provided a medicament dispenser for containing plural elongate form medicament carriers, each having multiple distinct medicament dose portions carried thereby, the dispenser having a housing of generally non-circular form, and within said housing a dispensing mechanism for dispensing the distinct medicament dose portions carried by each of said plural medicament carriers. The mechanism comprises at least one receiving station for receiving each of the plural medicament carriers; a release for releasing in combination a distinct medicament dose portion from each of the plural medicament carriers on receipt thereof by said receiving station; an outlet, positioned to be in communication with the distinct medicament dose portions releasable by said release; and at least one indexer for individually indexing the distinct medicament dose portions of each of the plural medicament carriers. The dispenser contains plural elongate form medicament carriers, each having multiple distinct dose portions carried thereby. At least one of said medicament carriers has the form of a continuous loop.
Inventor(s):	Augustyn; Stephen (Milton Keynes, GB), Davies; Michael Birsha (Ware, GB), Harvey; Stephen James (Ware, GB), Rand; Paul Kenneth (Ware, GB)
Assignee:	Glaxo Group Limited (Greenford, Middlesex, GB)
Application Number:	10/565,515
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,161,968
Patent Claim Types: see list of patent claims	Composition; Device;

Recent additions to Drugs Protected by US Patent 8,161,968

These patents are from the daily update and have not yet been integrated into the regular database

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER	205625	May 17, 2018	RX	Yes		Y
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER	205625	Aug 20, 2014	RX	Yes		Y

Drugs Protected by US Patent 8,161,968

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	203975-001	Dec 18, 2013		RX	Yes	Yes					Y
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-003	May 17, 2018		RX	Yes	Yes					Y
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-002	Aug 20, 2014		RX	Yes	Yes					Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-003	May 12, 2023		RX	Yes	No					Y

Foreign Priority and PCT Information for Patent: 8,161,968

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0317374.7	Jul 24, 2003

PCT Information
PCT Filed	July 21, 2004	PCT Application Number:	PCT/EP2004/008235
PCT Publication Date:	February 17, 2005	PCT Publication Number:	WO2005/014089

International Family Members for US Patent 8,161,968

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	495778
Australia	2004262907
Brazil	PI0411773
Canada	2533333